ISD

ISD Immunotherapeutics is a clinical-stage biotechnology company dedicated to developing first-in-class peptide therapeutics for severe autoimmune diseases. The company's lead candidate, ISD-017, is a proprietary peptide that specifically inhibits the STING (Stimulator of Interferon Genes) pathway, a central mediator of the innate immune response. By blocking STING-driven interferon production, ISD-017 aims to treat conditions like systemic lupus erythematosus (SLE) where the pathway is chronically overactivated. Headquartered in Denmark, the company leverages deep expertise in immunology and peptide chemistry to address high unmet medical needs in rheumatology. ISD is supported by a strong syndicate of life science investors, including Novo Holdings and Lundbeckfonden, to advance its pipeline through clinical proof-of-concept.